Managed Care Opportunities with Newer Therapies for Type 2 Diabetes
Jointly provided by
Impact Education, LLC     		This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

You Are Invited to a LIVE Free CME/CNE/CPE Webcast Series:

Managed Care Opportunities with Newer Therapies for Type 2 Diabetes
Track 1: The Impact of Newer T2DM Therapies and the Risk of Comorbidities
Track 2: Managed Care Decision Making in an Era of New T2DM Therapies

Live Webcast Dates

 Track 1
January 29, 2020 | 1:30pm to 3:00pm ET - Click Here to Complete Your Evaluation and Download Your Certificate

Track 2
February 13, 2020 | 11:30am to 1pm ET - Click Here to Complete Your Evaluation and Download Your Certificate

February 19, 2020 | 12:30pm to 2pm ET - Click Here to Complete Your Evaluation and Download Your Certificate

To join a webcast or complete an evaluation for a webcast you attended, please visit us at https://www.pathlms.com/impacteducation


LEARN ABOUT:
  • Recent and emerging cardiovascular outcome trial (CVOT) data
  • Recent T2DM treatment guideline updates and recommendations with managed care algorithms
  • Strategies that feature clinical and real-world evidence of the impact of newer agents
EXPERT FACULTY
John Buse, MD, PhD
Professor of Medicine, Executive Associate Dean for Clinical Research
University of North Carolina School of Medicine
Jeffrey Dunn, PharmD, MBA
(Formerly) Vice President, Clinical Strategy and Programs and Industry Relations
Magellan Rx Management
WHO SHOULD ATTEND?
  • Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
  • Pharmacy directors, specialty pharmacists, quality directors, care managers, registered nurses, and other managed care and payer organization professionals
PROGRAM OVERVIEW

Diabetes affects multiple organs systems and is associated with life-threatening complications such as chronic kidney disease and cardiovascular (CV) disease, including heart failure. Individuals with type 2 diabetes mellitus (T2DM) are 2-to-4 times more likely to develop and die from CV disease than their healthy peers. The financial burden associated with T2DM is significant; more than 20% of health care dollars are spent treating diabetes or its complications. These observations suggest a need to develop treatment strategies to mitigate T2DM disease progression as well as reduce the CV disease burden. This educational activity is designed to improve the knowledge and competence among managed care professionals and HCDMs regarding the potential impact of newer T2DM therapies (e.g., DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors) on CV and renal outcomes.

EDUCATIONAL OBJECTIVES

After completing the activity, participants should be better able to:
Track 1: The Impact of Newer T2DM Therapies and the Risk of Comorbidities
  • Discuss the relationship between diabetes, cardiovascular (CV) disease, heart failure (HF), and chronic kidney disease (CKD), and how newer therapies may reduce the risk of these outcomes
  • Review the recent and emerging cardiovascular outcome trial (CVOT) data
  • Integrate recent T2DM treatment guideline updates and recommendations with managed care algorithms for the management of comorbidities such as CV disease, HF, and CKD


Track 2: Managed Care Decision Making in an Era of New T2DM Therapies
  • Discuss the relationship between diabetes, cardiovascular (CV) disease, heart failure (HF), and chronic kidney disease (CKD), and how newer therapies may reduce the risk of these outcomes
  • Employ strategies that feature clinical and real-world evidence of the impact of newer agents on CV and renal outcomes
AGENDAS
Track 1: The Impact of Newer T2DM Therapies and the Risk of Comorbidities
Introduction - Initial Commentary & Overview
Jeffrey Dunn, PharmD, MBA
Reducing the Risk of Cardio-Renal Events with Newer Therapies
John Buse, MD, PhD
Integrating Treatment Guideline Updates with Managed Care Algorithms
Jeffrey Dunn, PharmD, MB
Faculty Idea Exchange & Audience Question and Answer Session
Closing Comments
Track 2: Managed Care Decision Making in an Era of New T2DM Therapies
Introduction - Initial Commentary & Overview
Jeffrey Dunn, PharmD, MBA
Defining the Implications of Recent CVOT Trials
John Buse, MD, PhD
Applying Real-World Evidence to Managed Care Decision Making
Jeffrey Dunn, PharmD, MB
Faculty Idea Exchange & Audience Question and Answer Session
Closing Comments
ACCREDITATION INFORMATION
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • Track 1: The Impact of Newer T2DM Therapies and the Risk of Comorbidities -1.5 CME Credits
  • Track 2: Managed Care Decision Making in an Era of New T2DM Therapies -1.5 CME Credits


Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Numbers:
  • Track 1: The Impact of Newer T2DM Therapies and the Risk of Comorbidities - JA4008162-9999-20-1028-L01-P, 1.5 contact hours (Application)
  • Track 2: Managed Care Decision Making in an Era of New T2DM Therapies - JA4008162-9999-20-1029-L01-P, 1.5 contact hours (Application)


Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.0 contact hours.
  • Track 1: The Impact of Newer T2DM Therapies and the Risk of Comorbidities - 1.5 contact hours (Application)
  • Track 2: Managed Care Decision Making in an Era of New T2DM Therapies - 1.5 contact hours (Application)

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Test your system at: http://bsb.adobeconnect.com/check.

Fee Information
There is no fee for this educational activity.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.